These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24206429)

  • 1. A new era of podocyte-targeted therapy for proteinuric kidney disease.
    Haraldsson B
    N Engl J Med; 2013 Dec; 369(25):2453-4. PubMed ID: 24206429
    [No Abstract]   [Full Text] [Related]  

  • 2. Abatacept in B7-1-positive proteinuric kidney disease.
    Benigni A; Gagliardini E; Remuzzi G
    N Engl J Med; 2014 Mar; 370(13):1261-3. PubMed ID: 24670179
    [No Abstract]   [Full Text] [Related]  

  • 3. Abatacept in B7-1-positive proteinuric kidney disease.
    Alachkar N; Carter-Monroe N; Reiser J
    N Engl J Med; 2014 Mar; 370(13):1263-4. PubMed ID: 24670180
    [No Abstract]   [Full Text] [Related]  

  • 4. Abatacept in B7-1-positive proteinuric kidney disease.
    Greka A; Weins A; Mundel P
    N Engl J Med; 2014 Mar; 370(13):1263-6. PubMed ID: 24670178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept in B7-1-positive proteinuric kidney disease.
    Yu CC; Fornoni A; Weins A; Hakroush S; Maiguel D; Sageshima J; Chen L; Ciancio G; Faridi MH; Behr D; Campbell KN; Chang JM; Chen HC; Oh J; Faul C; Arnaout MA; Fiorina P; Gupta V; Greka A; Burke GW; Mundel P
    N Engl J Med; 2013 Dec; 369(25):2416-23. PubMed ID: 24206430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocyte-Targeted Treatment for Proteinuric Kidney Disease.
    Mundel P
    Semin Nephrol; 2016 Nov; 36(6):459-462. PubMed ID: 27987545
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of B7-1 in proteinuria of glomerular origin.
    Novelli R; Benigni A; Remuzzi G
    Nat Rev Nephrol; 2018 Sep; 14(9):589-596. PubMed ID: 29959373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costimulatory receptor B7-1 is not induced in injured podocytes.
    Baye E; Gallazzini M; Delville M; Legendre C; Terzi F; Canaud G
    Kidney Int; 2016 Nov; 90(5):1037-1044. PubMed ID: 27528551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?
    Salant DJ
    J Am Soc Nephrol; 2016 Apr; 27(4):963-5. PubMed ID: 26400567
    [No Abstract]   [Full Text] [Related]  

  • 10. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
    Novelli R; Gagliardini E; Ruggiero B; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2016 Mar; 310(5):F335-41. PubMed ID: 26697986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report.
    Alkandari O; Nampoory N; Nair P; Atta A; Zakaria Z; Mossad A; Yagan J; Al-Otaibi T
    Exp Clin Transplant; 2016 Aug; 14(4):456-9. PubMed ID: 25432003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
    Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteinuria: abate or applaud abatacept in proteinuric kidney disease?
    Reiser J; Alachkar N
    Nat Rev Nephrol; 2014 Mar; 10(3):128-30. PubMed ID: 24375054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Grellier J; Del Bello A; Milongo D; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Sep; 28(9):1109-10. PubMed ID: 25847461
    [No Abstract]   [Full Text] [Related]  

  • 15. Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice.
    Kasai M; Kumano K; Kurasawa K; Nakao A; Saito Y; Iwamoto I
    Int Arch Allergy Immunol; 1998 Sep; 117 Suppl 1():14-9. PubMed ID: 9758890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of B7 costimulation in T-cell immunity.
    Harris NL; Ronchese F
    Immunol Cell Biol; 1999 Aug; 77(4):304-11. PubMed ID: 10457196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.
    Delville M; Baye E; Durrbach A; Audard V; Kofman T; Braun L; Olagne J; Nguyen C; Deschênes G; Moulin B; Delahousse M; Kesler-Roussey G; Beaudreuil S; Martinez F; Rabant M; Grimbert P; Gallazzini M; Terzi F; Legendre C; Canaud G
    J Am Soc Nephrol; 2016 Aug; 27(8):2520-7. PubMed ID: 26701979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts).
    D'Agati VD
    Kidney Int; 2008 Feb; 73(4):399-406. PubMed ID: 17989648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
    Chan AC
    Sci Transl Med; 2011 Jun; 3(85):85ps21. PubMed ID: 21632983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance.
    Romo-Tena J; Gómez-Martín D; Alcocer-Varela J
    Autoimmun Rev; 2013 Oct; 12(12):1171-6. PubMed ID: 23851140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.